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Despite the fact that several natural products (e.g. crude extracts or puriﬁed compounds) have been
found to activate cell antioxidant responses and/or delay cellular senescence the effect(s) of small
peptides on cell viability and/or modulation of protective mechanisms (e.g. the proteostasis network)
remain largely elusive. We have thus studied a hexapeptide (Hexapeptide-11) of structure Phe–Val–Ala–
Pro–Phe–Pro (FVAPFP) originally isolated from yeast extracts and later synthesized by solid state
synthesis to high purity. We show herein that Hexapeptide-11 exhibits no signiﬁcant toxicity in normal
human diploid lung or skin ﬁbroblasts. Exposure of ﬁbroblasts to Hexapeptide-11 promoted dose and
time-dependent activation of proteasome, autophagy, chaperones and antioxidant responses related
genes. Moreover, it promoted increased nuclear accumulation of Nrf2; higher expression levels of pro-
teasomal protein subunits and increased proteasome peptidase activities. In line with these ﬁndings we
noted that Hexapeptide-11 conferred signiﬁcant protection in ﬁbroblasts against oxidative-stress-
mediated premature cellular senescence, while at in vivo skin deformation assays in human subjects it
improved skin elasticity. Finally, Hexapeptide-11 was found to induce the activity of extracellular MMPs
and it also suppressed cell migration. Our presented ﬁndings indicate that Hexapeptide-11 is a promising
anti-ageing agent.
& 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Ageing is driven by diverse molecular pathways and bio-
chemical events that are promoted by both genetic and environ-
mental factors [1,2]. Speciﬁcally, ageing is deﬁned as a time-
dependent decline of stress resistance and functional capacity,
associated with increased probability of morbidity and mortality.
These effects relate to (among others) age-related gradual accu-
mulation of damaged biomolecules (including proteins) whichn open access article under the CC
cn1, beclin-1; ctsl, cathepsin-
ER, endoplasmic reticulum;
broblasts; hsf1, heat shock
, Kelch-like ECH-associated
Nrf2, NF-E2-related factor 2;
etwork; ROS, reactive oxygen
n reductase 1; UPS, ubiquitineventually compromise cellular homeodynamics as they result in
failure of most cellular maintenance pathways.
Considering that most (if not all) of the critical cellular func-
tions depend on the functionality of highly sophisticated protein
machines [3] it is not surprising that proteostasis (proteome
homeodynamics) regulation is critical for cellular functionality and
consequently for the overall healthspan and/or longevity of the
organism. To maintain proteostasis cells have developed a mod-
ular, yet integrated system which ensures general proteome
quality control and it is called the proteostasis network (PN) [3–6].
The PN curates the basal functionality of the proteome and it also
responds to conditions of proteotoxic stress by addressing the
triage decision of fold, hold, or degrade. PN is constituted from
several complex protein machines that ensure normal proteome
synthesis and recycling, or respond to conditions of proteotoxic
stress by launching the proteome damage responses (PDR), which,
ﬁrstly identify, and then, either rescue or degrade unfolded, mis-
folded or non-native polypeptides. Additional integrated modulesBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lular stress (e.g. heat or oxidative) responses which mobilize the
proteome caretakers; mitotic cells can also dilute proteome
damage by mitosis [3,6,7].
Central to the PN functionality and PDR are the two main
proteolytic systems namely the autophagy lysosome (ALS) and the
ubiquitin-proteasome (UPS) systems. ALS is mostly involved in the
degradation of long-lived proteins, aggregated ubiquitinated pro-
teins, as well as in the recycling of damaged organelles [8,9]. On
the other hand, UPS curates proteome stability in various sub-
cellular sites including the nucleus, the cytosol, the endoplasmic
reticulum (ER) and mitochondria. UPS is the main site of protein
synthesis quality control (at the cytosol and the ER) and it is also
involved in the recycling of both normal short-lived proteins and
of non-repairable misfolded or unfolded proteins [10–12]. The UPS
functionality and activity decline during either cellular senescence
or in vivo ageing [13–15] indicating that UPS is actively involved in
the molecular process that are linked with the appearance and,
likely, the progression of the ageing phenotypes. On the other
hand, UPS activation has been linked to prolonged efﬁcient
removal of damaged and/or dysfunctional polypeptides and it is
thus anticipated that this strategy will likely, exert anti-ageing
effects [11,12].
A number of small molecules, namely natural products (e.g.
crude extracts or puriﬁed compounds) isolated from various
sources (e.g. plants, microorganisms, marine organisms, etc.) were
found to delay either cellular senescence of normal human cells or
in vivo ageing of model organisms [1]. Natural compounds
represent an extraordinary inventory of high diversity structural
scaffolds and seemingly they affect the process of ageing or cel-
lular senescence by either intervening with nutrient sensing
pathways (e.g. the INS/IGF-1 pathway) or by activating stress
sense/response pathways; namely Sirtuins, the AMP-dependent
kinase or the FOXO and Nrf2 transcription factors [1].
Notably, the effects of small peptides on normal human cells
viability, cellular senescence and/or modulation of protective
mechanisms (e.g. the proteostasis network) remain largely elusive.
In few previous studies it was found that extracts from Sacchar-
omyces cerevisiae fermentation exert wound healing properties
[16–18]. These properties were attributed to improved collagen
synthesis [16,18] and to increased cellular oxygen consumption
[19,20]. We have studied a hexapeptide (Hexapeptide-11) of
structure Phe–Val–Ala–Pro–Phe–Pro (FVAPFP) that was isolated
from yeast extracts and later synthesized by solid state synthesis
to high purity; this peptide seemed particularly interesting since
its amino acid sequence was found in various proteins including
stress- or proteostasis-related proteins (e.g. the molecular cha-
perone, hsp70) (our unpublished data). We report herein the
impact of the hexapeptide FVAPFP on normal human cells pro-
teostasis and anti-oxidant modules and its capacity to exert anti-
ageing effects in normal human cells.Materials and methods
Cell lines and cell culture conditions
Human lung embryonic (IMR90 cells) and human newborn
foreskin (BJs) ﬁbroblasts were obtained from the American Tissue
Culture Collection and were maintained in Dulbecco's modiﬁes
Eagle's medium (Gibco Life Technologies), supplemented with 10%
(v/v) fetal bovine serum, 2 mM glutamine and 1% non-essential
amino acids in a humidiﬁed incubator at 5% CO2 and 37 °C. In all
experimental procedures proliferating cells were subcultured at a
split ratio 1:2 (when conﬂuent) by using a trypsin/EDTA solution
(Gibco Life Technologies).Induction of premature senescence by H2O2 and SA β-Gal staining
Stress-induced premature senescence (SIPS) in relatively early
passage proliferating cells was induced by exposing subconﬂuent
cell cultures to serial short term oxidative stress as previously
described [21] with minor modiﬁcations. Brieﬂy, cells were treated
with a subcytotoxic concentration of 300 mM H2O2 (three expo-
sures of 48 h each); also, in this series of experiments cells were
treated for the same periods with 5% (v/v) (see below) Hexapep-
tide-11 or with both 300 mM H2O2/5% (v/v) Hexapeptide-11. Con-
trol cells were kept under the same culture conditions without
H2O2.
Senescent cells were stained with β-galactosidase staining as
described previously [21,22]. Brieﬂy, cells were washed with PBS
and ﬁxed in 0.2% glutaraldehyde and 2% formaldehyde in PBS for
5 min. Following ﬁxation cells were washed with PBS and were
then stained (in the absence of CO2) for 12–16 h at 37 °C in
staining solution [150 mM NaCl, 2 mM MgCl2, 5 mM K3Fe(CN)6,
5 mM K4[Fe(CN)6] 3H2O, 40 mM citric acid/sodium phosphate, pH
6.0 containing 1 mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galacto-
side]. Cells were viewed under phase contrast optics in a TS-100F
NIKON inverted microscope and at least 10 optical ﬁelds were used
to score positively stained cells.
Cell survival assay
Cells were plated in ﬂat-bottomed 96-well microplates. After
24 h they were treated with different concentrations of Hex-
apeptide-11 for 24 or 48 h. Following the completion of the
treatment the medium was replaced by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) dis-
solved at a ﬁnal concentration of 1 mg/mL in serum-free, phenol
red–free medium. The reduction of the dye by the living cells was
allowed to take place for 3–4 h. The MTT solution was discarded
and isopropanol was added to dissolve the formazan crystals. The
absorbance of the solution was measured at 570 nm wavelength.
Survival of control cells was arbitrarily set to 100%.
Yeast (S. cerevisiae) culture and peptide synthesis
Hexapeptide-11 was initially manufactured by using fermen-
tation biotechnology; the resulting fermentation product was
fractionated using proprietary ﬁltration and chromatography to
isolate the desired dominant peptide, which was then separated
from the crude mixture and isolated in a highly puriﬁed state as
described previously [23]. The isolated peptide was sequenced and
the sequence of Hexapeptide-11 was found to be of the speciﬁc
amino acid sequence Phe–Val–Ala–Pro–Phe–Pro. The peptide
(named as Hexapeptide-11) was later synthesized by solid state
synthesis to high purity, as described previously [23], and was
then diluted in sterile H2O at a stock solution concentration of
295 mM. The % (v/v) concentration of Hexapeptide-11 that is
indicated in text or ﬁgures refers to percent by volume of the
sterile 295 mM stock solution of Hexapeptide-11 in the total
volume of cell culture medium.
RNA extraction, cDNA synthesis and quantitative Real Time PCR (Q-
PCR) analysis
Total RNA was isolated using the TRI Reagent
s
RNA Isolation
Reagent (Sigma-Aldrich) and quantiﬁed with BioSpec-nano spec-
trophotometer (Shimadzu Inc.). Subsequently, 1 mg RNA was con-
verted to cDNA with the Maxima First Strand cDNA Synthesis Kit
for RT-qPCR (Thermo Scientiﬁc). Real-time PCR was performed
using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scien-
tiﬁc) and the PikoReal 96 Real-Time PCR System (Thermo
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(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and are descri-
bed in Supplemental data.
Immunoblotting analysis
Cells were lysed in a buffer containing 150 mM NaCl, 1% Non-
idet P-40, 0.1% SDS, 50 mM Tris–HCl, pH 8.0 and phosphatase,
protease inhibitors; cell lysates were immediately cleared with
centrifugation for 15 min at 19,000g (4 °C). After adjustment of
protein content with the Bradford method (Bio-Rad Laboratories),
samples were mixed with reducing Laemmli buffer and equal
protein amounts were fractionated by SDS-PAGE followed by
immunoblotting, as described previously [24]. Primary and
horseradish peroxidase-conjugated secondary antibodies were
applied for 1 h at RT and immunoblots were developed by an
enhanced chemiluminescence reagent kit (Santa Cruz
Biotechnology).
Measurement of proteasome enzymatic activities
Cells were lysed on ice by using a buffer suitable for the iso-
lation of 26S proteasome (0.2% Nonidet P-40, 5 mM ATP, 10% gly-
cerol, 20 mM KCl, 1 mM EDTA, 1 mM dithiothreitol, and 20 mM
Tris, pH 7.6). Lysates were cleared with centrifugation at 19,000g
(4 °C), and, after protein content adjustment with Bradford,
supernatants were immediately used to determine the three
proteasome proteolytic activities as described previously [14,25].
Brieﬂy, the chymotrypsin-like (CT-L/LLVY), caspase-like (C-L/LLE)
and trypsin-like (T-L/LRR) activities were assayed by recording the
hydrolysis of the ﬂuorogenic peptides Suc–Leu–Leu–Val–Tyr–
AMC, Z-Leu–Leu–Glu–AMC, and Boc–Leu Arg–Arg–AMC (Enzo Life
Sciences, Farmingdale, NY, USA), respectively, at 37 °C for 3 min.
The ﬂuorescence was measured at a VersaFluorTM Fluorometer
System (Bio-Rad laboratories, Hercules, CA, USA) at excitation and
emission wavelengths of 350 and 440 nm, respectively.
Measurement of cathepsins B, L enzymatic activities
The cathepsin B, L activity was measured as described pre-
viously [26] with minor modiﬁcations. Brieﬂy, cells were lysed on
ice in 1 mM dithiothreitol and 50 mM Tris, pH 4.0 and the lysates
were cleared at 14,000g for 20 min at 4 °C. Following protein
content measurement with Bradford assay (Bio-Rad), 20 mg of
protein were incubated in the reaction buffer (50 mM sodium
acetate, 8 mM cysteine-hydrochloride, 1 mM EDTA, pH 4.0) con-
taining the substrate z-FR-AMC (Enzo Life Sciences) for 30 min at
37 °C. The ﬂuorescence was measured (VersaFluorTM Fluorometer
System) at excitation and emission wavelengths of 350 and
440 nm, respectively.
Immunoﬂuorescence staining
Cells grown on coverslips were ﬁxed in 4% formaldehyde in PBS
and permeabilized with 0.2% Triton X-100. Blocked cells (1% BSA in
PBS) were then incubated with primary anti-Nrf2 antibody (sc-
722, Santa Cruz; diluted 1:100) and secondary antibody (anti-
rabbit-IgG, Texas Red, diluted 1:200) for 1 h at RT. For visualizing
nuclei cells were counterstained with DAPI (Molecular Probes).
Samples were viewed at an Eclipse TS-100F NIKON inverted
ﬂuorescent microscope.
Cell migration assay
The migration capacity of treated (or control) cells was eval-
uated by using the in vitro scratch assay as described previously[27]. Cells were plated in 60 mm dishes and left to grow until they
reached conﬂuency. Then, the conﬂuent monolayer was scratched
down with a 200 mL sterile pipette tip. After scratching, plates
were washed once with culture medium to remove ﬂoating cells
and cells were fed with fresh medium containing (or not) Hex-
apeptide-11. Cells were allowed to migrate across the wound and
micrographs were taken at various time points by using phase
contrast optics at an Eclipse TS-100F NIKON inverted microscope.
Assessment of MMP-2 and MMP-9 activities by gelatin zymography
The gelatinases MMP-2 and MMP-9 activity in cell-conditioned
media was evaluated by gelatin zymography. Cell culture super-
natants were subjected to SDS-PAGE on a 10% SDS-polyacrylamide
gel impregnated with 1 mg/mL gelatin in the presence of 0.1% SDS
(under non-reducing conditions). After electrophoresis, gels were
washed in 5 mmol/L CaCl2, 50 mmol/L Tris–HCl, pH 7.4 containing
2.5% Triton X-100 for 1 h at RT, with gentle agitation to remove
SDS. Gels were then incubated for 40 h at 37 °C in the reaction
buffer containing 5 mmol/L CaCl2, 50 mmol/L Tris–HCl, pH 7.4.
Afterwards, gels were stained with a 0.5% Coomassie Brilliant Blue
solution containing 20% methanol and 10% acetic acid and
destained with 30% methanol and 10% acetic acid. The gelatinolytic
activity was detected as clear bands against the blue background.
Measurement of skin ﬁrmness in human subjects
The skin ﬁrming properties of Hexapeptide-11 were evaluated
by conducting an in vivo study on 25 volunteers according to
standard ethical procedures (Lonza Personal Care, USA). A ﬁrming
toner containing 2.8% (v/v) Hexapeptide-11 (or a control toner
with no Hexapeptide-11) was applied twice daily around the eyes
and cheeks for 4 weeks. An estimated concentration of the used
preparation was 2 mg/cm2 of skin (mass/skin area). The ﬁrmness
of the skin was analyzed using a Cutometer SEM 575 Skin Elasti-
city Meter; this device measures the rheological properties of the
skin, looking for the elastic and viscous response of the skin to
externally applied stress (i.e. a gentle twisting of the skin). The
initial elastic response of the skin is called Ue and the total
deformation response (i.e. the ability of the skin to rebound from
the twist) called Uf. A typical measurement only requires a few
seconds to complete.Antibodies used
Primary antibodies against human Nrf2 (sc-722), proteasome
α7 subunit (sc-100456), proteasome β5 subunit (sc-55009), Nqo1
(sc-16464), beclin-1 (sc-11427), p53 (sc-47698), p21CIP1 (sc-6246),
and GAPDH (sc-25778), as well as the HRP-conjugated secondary
antibodies were purchased from Santa Cruz Biotechnology.
Statistical analysis
Experiments were performed at least in duplicates unless
otherwise indicated in ﬁgure legends. For statistical analyses MS
Excel and the Statistical Package for Social Sciences (IBM SPSS;
version 19.0 for Windows) were used. Statistical signiﬁcance was
evaluated using one-way analysis of variance (ANOVA). Data
points correspond to the mean of the independent experiments
and error bars denote standard deviation (SD.); signiﬁcance at
Po0.05 or Po0.01 is indicated in graphs by one or two asterisks,
respectively.
A.D. Sklirou et al. / Redox Biology 5 (2015) 205–215208Results
Hexapeptide-11 shows no toxicity to human ﬁbroblasts and promotes
dose and time-dependent induction of proteasome, autophagy, cha-
perones and antioxidant responses related genes
We ﬁrst set out to examine the effect of Hexapeptide-11 on the
viability of human lung IMR90 (Fig. 1A) and skin BJ (Fig. 1B)
ﬁbroblasts. To this end, cells were incubated with increasing
concentrations of Hexapeptide-11 for 24 or 48 h and, as shown in
Fig. 1, up to (at least) the concentration of 5% (v/v), this peptide
exerted no signiﬁcant cytotoxic effect on human ﬁbroblasts;
notably at low concentrations in IMR90 cells Hexapeptide-11
seemed to even slightly enhance cell viability (Fig. 1A). The indi-
cated % (v/v) concentration hereafter refers to percent by volume
of the stock Hexapeptide-11 solution (295 mM) in the total volume
of cell culture medium.
Given the absence of cytotoxicity we then sought to investigate
the effect(s) of Hexapeptide-11 on the expression of genes
involved in the PN modules. As shown in Fig. 2 Q-PCR analyses
revealed that exposure of proliferating IMR90 cells to Hexapep-
tide-11 induced the expression of 20S and 19S proteasome sub-
units genes (α7, β1, β2, β5, rpn6, rpn11); of genes involved in ALS
functionality (i.e. becn1, sqstm1 and hdac6, along with the cathe-
psins ctsl and ctsd) and it also resulted in the upregulation of
molecular chaperones genes (hsf1, hsp27, hsp70, hsp90 and clu), as
well as of genes that are functionally involved in cellular anti-
oxidant responses, namely nrf2 and keap1, along with downstream
transcriptional targets of Nrf2 (i.e. the nqo1 and txnrd1 genes).
Notably, in most cases upregulation of the studied genes was dose-
dependent. Prolonged exposure of IMR90 cells to Hexapeptide-11Fig. 1. Hexapeptide-11 does not exert any signiﬁcant toxicity in normal human diploi
[IMR90, (A)] or skin [BJ, (B)] ﬁbroblasts exposed to the indicated concentrations of Hex
centration refers to percent by volume of the stock Hexapeptide-11 solution in the total
100%.for 96 h enhanced signiﬁcantly the intensity [especially at the
concentration of 5% (v/v)] of the studied genes upregulation
(Supplementary Fig. S1), indicating the existence of, not only dose-
dependent, but also time-dependent effects on gene expression
patterns. To exclude the possibility of a cell type-speciﬁc effect we
also studied the impact of Hexapeptide-11 in human skin ﬁbro-
blasts (BJ cells). As shown in Supplementary Fig. S2, exposure of BJ
cells to Hexapeptide-11 for 24 h also promoted the upregulation of
PN related genes, namely proteasome, ALS-related, antioxidant
responses and molecular chaperones genes.
Hexapeptide-11 enhances Nrf2 nuclear accumulation; induces higher
expression levels of proteasomal protein subunits and increases pro-
teasome peptidase activities
Considering the induction of transcriptional targets of Nrf2 (i.e.
nqo1 and txnrd1) after cell exposure to Hexapeptide-11, we then
investigated the protein expression of Nrf2 along with its sub-
cellular distribution in IMR90 cells exposed for 24 h to either
150 mM H2O2 or to (2%, 5% v/v) Hexapeptide-11. As shown in Fig. 3
A1 Hexapeptide-11 (mainly at the 5% concentration) induced a
mild induction in the expression of the Nrf2 protein, while
immunoﬂuorescence studies revealed that (as in the case of H2O2
treatment) Hexapeptide-11 enhanced the nuclear accumulation of
Nrf2; this effect was more prominent in cells treated with 5% (v/v)
Hexapeptide-11 (Fig. 3A2). Moreover, in support to our afore-
mentioned gene expression analyses, cell treatment with Hex-
apeptide-11 for 24 h induced higher expression levels of the 20S
α7 proteasomal subunit (Fig. 3B).
We then investigated the molecular effects that are induced in
IMR90 cells after more prolonged exposures to Hexapeptide-11. Asd ﬁbroblasts. (A, B) Relative (%) survival (MTT assay) of proliferating human lung
apeptide-11 for 24 (left panels) or 48 (right panels) h. The indicated % (v/v) con-
volume of cell culture medium. Bars, 7SD. *, Po0.05; **, Po0.01 vs. controls set to
Fig. 2. Exposure of IMR90 cells to Hexapeptide-11 for 24 h results in the upregulation (mostly dose dependent) of genes involved in the proteostasis network regulation, as
well as in cellular antioxidant responses. Shown Q-PCR gene expression analyses refer to 20S and 19S proteasome genes (α7, β1, β2, β5, rpn6, and rpn11); to genes involved in
ALS functionality (becn1, sqstm1, hdac6, ctsl and ctsd) and in molecular chaperones (hsf1, hsp27, hsp70, hsp90 and clu), as well as to genes involved in antioxidant responses
(nrf2, keap1, nqo1 and txnrd1). The beta-2-microglobulin (b2m) gene expression was used as normalizer; shown % v/v) concentration of Hexapeptide-11 is as in Fig. 1. Bars,
7SD. *, Po0.05; **, Po0.01 vs. controls set to 1.
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72 h induced higher protein expression levels of the 20S protea-
some subunits β5 and α7, as well as of the antioxidant protein
Nqo1 (Fig. 4A1); it also promoted a dose- and time-dependent
induction of (mainly) the LLVY/β5 proteasome peptidase activity(Fig. 4A2). On the other hand, Hexapeptide-11 either suppressed
(at 2%) or had no signiﬁcant effect on the cathepsins B, L enzymatic
activity (Fig. 4B1); in support we noted no signiﬁcant differences
on the expression levels of the autophagy-related protein beclin-1
after cell exposure to 2% or to 5% (v/v) Hexapeptide-11 (Fig. 4B2).
Fig. 3. Treatment of IMR90 cells with Hexapeptide-11 for 24 h enhances Nrf2 nuclear accumulation and upregulates the protein expression levels of proteasomal subunits
(A1). Representative immunoblot analyses of Nrf2 expression in cells treated with 2% or 5% (v/v) Hexapeptide-11 (A2). Immunoﬂuorescence images following Nrf2 locali-
zation in early passage IMR90 ﬁbroblasts treated with the indicated concentrations of H2O2 or Hexapeptide-11; cells nuclei were counterstained with DAPI. Nrf2 is
increasingly distributed in the nucleus (arrows) in H2O2 or Hexapeptide-11 treated cells. (B) Immunoblot analysis of the 20S proteasome subunit α7 expression after cell
exposure to the indicated concentrations of Hexapeptide-11. GAPDH probing (A1, B) was used as reference for total protein input. Molecular weight markers (in kDa) are
indicated on the right of each blot; % (v/v) concentration of Hexapeptide-11 is as in Fig. 1. Bars, in (A2) 10 mM.
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senescence in normal human ﬁbroblasts, and improves skin elasticity
at in vivo skin deformation assays
Given our previous ﬁndings, we then addressed the question
whether Hexapeptide-11 could protect cells from oxidative stress
mediated premature senescence. To this end, we triggered SIPS
by treating (three exposures of 48 h each) young proliferating
IMR90 cells with 300 mM H2O2; in parallel cells were treated with
either 5% (v/v) Hexapeptide-11 or with 300 mM H2O2/5% (v/v)
Hexapeptide-11. As shown in Fig. 5A, SA-β-GAL staining revealed
that Hexapeptide-11 conferred signiﬁcant protection againstH2O2-mediated SIPS. Interestingly, via a currently unknown
mechanism, it also suppressed the H2O2 and SIPS-related p53 and,
its transcriptional target p21CIP1 upregulation in IMR90 cells
(Fig. 5B).
On the basis of these ﬁndings, and in order to explore the
potential skin ﬁrming properties of Hexapeptide-11 we conducted
an in vivo half-face study on 25 volunteers (see Materials and
methods). As shown in Fig. 5C we observed that the application of
a toner containing Hexapeptide-11 resulted in a signiﬁcant
improvement (vs. a control toner) in Ue (the initial elastic
response of the skin) but not of Uf (total deformation response)
after 4 weeks of treatment.
Fig. 4. Prolonged exposure of IMR90 ﬁbroblasts to Hexapeptide-11 upregulates proteasome protein subunits and the antioxidant protein Nqo1 and induces the chy-
motrypsin-like (LLVY/β5) proteasome peptidase activity in a dose-dependent manner (A1). Immunoblot analyses of the 20S proteasome protein subunits β5 and α7, as
well as of Nrf2 and Nqo1 in IMR90 cells treated for 48 h with the indicated concentrations of Hexapeptide-11 (A2). Enzymatic activities of the three (LLVY/β5, LLE/β1 and
LRR/β2) proteasome peptidases activities in early passage IMR90 cells treated for 48 and 72 h with 2% or 5% (v/v) Hexapeptide-11 (B1). Relative (%) cathepsin B, L activities
in sample preparations from IMR90 exposed to 2% or 5% (v/v) Hexapeptide-11 for 48 and 72 h (B2) immunoblot analyses of the autophagy related protein Beclin-1 in
IMR90 cells treated for 48 h with 2% or 5% (v/v) Hexapeptide-11. Proteasome and cathepsin activities were expressed in ﬂuorescence units per mg of input protein vs.
controls set to 100%. GAPDH probing in (A1, B2) was used as reference for total protein input. Molecular weight markers (in kDa) are indicated on the right of each blot;
shown % (v/v) concentration of Hexapeptide-11 is as in Fig. 1. Bars, 7SD (n¼2). *Po0.05 vs. controls set to 100%.
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of human ﬁbroblasts migration
Given the fact that Hexapeptide-11 has been found to inﬂuence
a number of genes that functionally relate to extracellular matrix
function (our unpublished ﬁndings), we then investigated the
effect of this peptide on the enzymatic activity of the gelatinases
MMP-2 and MMP-9. To this end, IMR90 cells were treated with
Hexapeptide-11 and after 24-h the conditioned media were sub-
jected to gelatin zymography. As it can be seen in Fig. 6A, cell
treatment with Hexapeptide-11 promoted a dose-dependent
increase in the enzymatic activity of both the MMP-2 and MMP-9
gelatinases.
Given the fact that this ﬁnding indicated that Hexapeptide-11
could exert wound healing effects or even affect the migratory
activity of the IMR90 cells, we also performed an in vitro scratch
assay in order to investigate the impact of Hexapeptide-11 on
IMR90 migration. As it is shown in Fig. 6B we found that treatment
of IMR90 cells with Hexapeptide-11 rather decreased the IMR90
cells migratory activity.Discussion
Despite the cell-type speciﬁc differences that characterize the
manifestation of cellular senescence in mitotic and post-mitotic
human cell lineages, it is evident that, independently of the cell
type, the appearance of cellular senescence is marked by the
accumulation of damaged/dysfunctional biomolecules [28–30]. In
support, the rate of damaged biomolecules accumulation has been
found to increase in aged animal tissues and to correlate with
chronological ageing [15,25,31–33]. We report herein that a hex-
apeptide of structure Phe–Val–Ala–Pro–Phe–Pro (originally iso-
lated from yeast) could promote the generalized activation of
genes involved in the PN regulation, namely antioxidant respon-
ses, UPS, ALS and molecular chaperones. Moreover, it enhanced
the expression of proteasomal protein subunits and also of pro-
teasome peptidase activities (but not of lysosomal enzymes; e.g.
cathepsins). Loss of proteostasis is a common feature of ageing and
of age-related diseases (e.g. neurodegeneration or cancer) and is
characterized by the appearance of non-native proteins or protein
aggregates in various tissues. Likely, this relates to the fact that,
independently of the triggering event, senescent cells are
Fig. 5. Hexapeptide-11 protects IMR90 ﬁbroblasts from oxidative stress mediated premature senescence, while at in vivo skin deformation assays in human subjects it
improves skin elasticity (A1). Representative light ﬁeld images following SA-β-Gal staining of control IMR90 cells or cells treated (three exposures of 48 h each) with 300 mM
H2O2; 5% (v/v) Hexapeptide-11 or 300 mMH2O2/5% (v/v) Hexapeptide-11 (A2). Relative (%) number of SA-β-Gal positive cells (mean of 10 optical ﬁelds) following treatment of
cells exactly as in (A1). (B) Immunoblot analyses of p53 and p21CIP1 expression levels in cells treated as in (A); Hexapeptide-11 can inhibit the H2O2-mediated induction of
p53 and its transcriptional target p21CIP1. (C) Difference in lateral skin deformation (Ue, Uf parameters) after conducting an in vivo study on the eyes and cheeks of 25
volunteers for 4 weeks. The study was performed by using a preparation containing 2.8% (v/v) of Hexapeptide-11 (vs. control); a signiﬁcant improvement was found in Ue
(initial elastic response of the skin) but not in Uf (total deformation response) after 4 weeks of treatment. GAPDH probing (B) was used as reference for total protein input.
Shown % (v/v) concentration of Hexapeptide-11 is as in Fig. 1; molecular weight markers (in kDa) are indicated on the right of each blot. Bars, 7SD (n¼2). *Po0.05 vs.
controls set to 100%. Bars, in (A1) 10 mM.
A.D. Sklirou et al. / Redox Biology 5 (2015) 205–215212characterized by accumulation of oxidative stress, reduced pro-
teasome activity and high rates of genome/proteome instability
[3,11,12]; this was also evident in a recent comparative meta-
analysis of ours in human transcriptomics data during cellular
senescence and in vivo tissue ageing [34]. In line with these
ﬁndings it has been proposed that enhanced activity of the PN
could suppress the rate of ageing progression indicating that, the
PN functional modules may represent potential therapeutic targets
in the delay of ageing and/or the prevention of age-related
pathologies [3,6,7,35]. In support, we have observed that Hex-
apeptide-11 could protect normal human diploid ﬁbroblasts from
oxidants-mediated SIPS; the beneﬁcial effects of this peptide were
also evident in the studies in human volunteers showing an
improvement in the elastic response of the more superﬁcial layers
of the skin. Modulation of the PN is a rather novel property of
peptides from yeast cell derivatives, since (in the limited existing
studies) yeast peptides have been found to (mainly) stimulatewound healing [16,18]; it was also reported that peptides are
active in nanomolar amounts and are 600 times more active
than the initial extract [17]. On the other hand, a number of nat-
ural compounds (isolated from various sources including marine
organisms, microorganisms or plants) have been found to activate
the PN modules and exert anti-ageing effects both in vitro and
in vivo [1]. For instance, Rapamycin was (among others) found to
enhance longevity of Caenorhabditis elegans in an SKN-1/Nrf2
dependent fashion [36], while oral administration of rapamycin in
adult Drosophila ﬂies resulted in lifespan extension that was
associated with increased resistance to both starvation and oxi-
dative stress. Moreover, Quercetin enhanced proteasome activity,
conferred resistance to oxidative stress and extended the replica-
tive lifespan of human ﬁbroblasts [37], while Icariside II when
tested in C. elegans increased thermo and oxidative stress toler-
ance, decreased the rate of locomotion decline in late adulthood
and extended worms’ lifespan [38]; it was postulated that the
Fig. 6. Treatment of IMR90 cells with Hexapeptide-11 activates the MMPs 2 and 9 and it also suppresses cellular migratory activity. (A) Assessment (by gelatin
zymography) of the gelatinases MMP-2 and MMP-9 enzymatic activity following cell treatment with 1%, 2% or 5% (v/v) Hexapeptide-11 for 24 h. (B) Representative phase
contrast images showing cellular migratory activity 24–72 h after a scratch assay in conﬂuent IMR90 cells; cells were treated with 1%, 2% or 5% (v/v) Hexapeptide-11 as
indicated. Shown % (v/v) concentration of Hexapeptide-11 is as in Fig. 1; bars, in (B) 100 mM.
A.D. Sklirou et al. / Redox Biology 5 (2015) 205–215 213lifespan extension caused by icariside II was dependent (among
others) on the hsf1 signaling pathway. Finally, Oleuropein, the
major constituent of Olea europea leaf extract, when studied for its
cell protective effects in human ﬁbroblasts was found to suppress
oxidative stress, reduce protein oxidation, activate the proteasome
and delay the appearance of cellular senescence [39].
Intriguingly, we found that Hexapeptide-11 activated the MMP-
2/MMP-9 metalloproteinases and suppressed ﬁbroblasts migra-
tion. In previous studies increased secretion of tissue inhibitors of
metalloproteinases 1 and 2 (TIMPs 1 and 2) in ﬁbroblasts were
found to represent early indicators of oral sub-mucous ﬁbrosis and
ageing [40]; this ﬁnding indicated that MMPs activation may
represent an anti-ageing adaptation. In support, low-level laserimproved tendon healing via an increase of MMPs activity and
collagen synthesis [41], while resveratrol induced MMP-9 and cell
migration via p38 kinase and PI3K pathways in human ﬁbro-
sarcoma cells [42]. On the other hand, it has been found that a
subfragment of the carboxyl-terminal propeptide of type I collagen
dramatically augmented extracellular matrix production in sub-
conﬂuent ﬁbroblasts [43], while the pentapeptide Lys–Thr–Thr–
Lys–Ser is the minimum sequence necessary for potent stimula-
tion of collagen and ﬁbronectin production in a variety of
mesenchymal cells [19]. Overall, MMPs activation by Hexapeptide-
11 may indicate wound healing properties which are, however,
contradicted by the inhibitory effect that this peptide exerted on
cells migratory activity.
A.D. Sklirou et al. / Redox Biology 5 (2015) 205–215214Mechanistically, the mode of Hexapeptide-11 action remains
elusive. Our ﬁnding that it suppressed the H2O2-mediated p53 and
p21 upregulation corroborates a recent study showing that Hex-
apeptide-11 downregulated ataxia telangiectasia mutated (ATM)
and p53 protein expression in human dermal ﬁbroblasts [23].
Interestingly, BLAST alignment analyses (in order to match this
peptide sequence against the entire proteome dataset) revealed
that the unique sequence of amino acids that comprise Hex-
apeptide-11 appear in a number of proteins of S. cerevisiae
including a major module of the PN, namely hsp70. Thus, this
peptide may, at least in part, exert its effects by acting as a pseudo-
signal of chaperones activation which then triggers a cascade of a
more generalized activation (in an alarm state) of additional PN
modules. Alternatively, Hexapeptide-11 may function as a “low-
dose stressor” that pre-condition cells to resist more severe stress
(i.e. by exerting a hormetic effect) [44].
In summary, and despite a number of critical questions in
relation to the mechanistic aspects of Hexapeptide-11 action (that
certainly need further extensive investigations) this peptide
represents a molecule which, likewise a novel hsf1 activator [45],
can activate the cellular PN machineries in a dose- and time-
dependent fashion. Thus, Hexapeptide-11 is a promising anti-
ageing agent for further testing which may play a role in
improving human skin health and integrity.Conﬂict of interest
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